Pharmacological inhibition of UHRF1 and DNMT activity inhibits ESCC growth, which may represent a promising therapeutic approach to treat ESCC patients dependent on NKX2‐5/LHX1/UHRF1 transcription axis for the maintenance of the oncogenic state. Here, NKX2-5 is linked to esophageal squamous cell carcinoma.